Cooley M&A

JANUARY 23, 2024

Also significant, after the FTC filed suit to block an agreement whereby Maze would have granted Sanofi an exclusive license to Maze’s drug candidate for the treatment of Pompe disease, arguing it would eliminate a nascent competitor, Sanofi decided not to contest the litigation and terminated the agreement. billion.

Marketability 52

Marketability Equity Private Equity Firm Finance 52

Harvard Corporate Governance

AUGUST 5, 2022

by Sanofi, S.A. The Goldstein v. Denner (May 26, 2022) litigation arose out of the $11.6 billion cash acquisition of Bioverative, Inc. which had recently been spun off from Biogen, Inc.)

200

200

Reynolds Holding

OCTOBER 5, 2022

May 26, 2022), a stockholder plaintiff adequately pleaded that certain members of Bioverativ’s board breached their fiduciary duties during a process to sell the company to Sanofi. Aspects of the decision in Goldstein suggest this is a topic that the court may be interested in exploring more in the future. at *2–3, *46, *50.

Start-ups 72

Start-ups Marketability Equity Compliance 72

Reynolds Holding

JANUARY 21, 2024

The Year Ahead In 2024, transaction parties should anticipate close scrutiny of transactions with inquiries into topics such as labor, research and development, post-transaction governance, and the competitive dynamics surrounding the parties’ “ecosystem.”

Marketability 45

Marketability Technology Equity 45